Celgene remains undervalued at current levels, says RW Baird Baird believes Celgene remains undervalued despite its recent performance. The firm cited numerous upcoming catalysts which will have profound implications for intermediate to longer term revenue. Shares are Outperform rated with a $130 price target.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.